Abstract
This article describes recent advances in the development and biological evaluation of allosteric and ATP-competitive small molecule inhibitors for the serine/threonine kinase Akt (protein kinase B, PKB). Unregulated activation of the PI3K/Akt/PTEN pathway is a prominent feature of many human cancers and Akt is over-expressed or activated in all major cancers making Akt an exciting new target for cancer therapy. The development of Akt inhibitors has been complicated and hampered by the presence of three Akt isozymes, (Akt1, Akt2 and Akt3) which differ in function and tissue distribution, as well as a lack of Akt specific inhibitors. In the past 18 months, a large number of reports have appeared describing the discovery and development of allosteric Akt kinase inhibitors and classical ATPcompetitive Akt kinase inhibitors. This review will discuss the PI3K/Akt/PTEN pathway, allosteric and ATP-competitive Akt kinase inhibitors, their biological evaluation and progress towards target validation.
Keywords: Akt, PKB, cancer, chemotherapy, apoptosis, allosteric, inhibitors, kinase
Current Cancer Drug Targets
Title: The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Volume: 8 Issue: 1
Author(s): Craig W. Lindsley, Stanley F. Barnett, Mark E. Layton and Mark T. Bilodeau
Affiliation:
Keywords: Akt, PKB, cancer, chemotherapy, apoptosis, allosteric, inhibitors, kinase
Abstract: This article describes recent advances in the development and biological evaluation of allosteric and ATP-competitive small molecule inhibitors for the serine/threonine kinase Akt (protein kinase B, PKB). Unregulated activation of the PI3K/Akt/PTEN pathway is a prominent feature of many human cancers and Akt is over-expressed or activated in all major cancers making Akt an exciting new target for cancer therapy. The development of Akt inhibitors has been complicated and hampered by the presence of three Akt isozymes, (Akt1, Akt2 and Akt3) which differ in function and tissue distribution, as well as a lack of Akt specific inhibitors. In the past 18 months, a large number of reports have appeared describing the discovery and development of allosteric Akt kinase inhibitors and classical ATPcompetitive Akt kinase inhibitors. This review will discuss the PI3K/Akt/PTEN pathway, allosteric and ATP-competitive Akt kinase inhibitors, their biological evaluation and progress towards target validation.
Export Options
About this article
Cite this article as:
Lindsley W. Craig, Barnett F. Stanley, Layton E. Mark and Bilodeau T. Mark, The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497096
DOI https://dx.doi.org/10.2174/156800908783497096 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Green Chemistry Starting from 2H-Pyran-2-one Derivatives
Current Green Chemistry STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Recent Advances in Formation, Properties, and Applications of Polymersomes
Current Pharmaceutical Design NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry In Silico Prediction Models for Blood-Brain Barrier Permeation
Current Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies
Current Neuropharmacology Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations
Current Cancer Drug Targets